drugset
drugset / Trial / NCT03917628

Pharmacokinetics and Safety in Healthy Volunteers

NCT03917628 ↗

Phase 1 Completed 146 enrolled Sinocelltech Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

Investigate the pharmacokinetics, safety and tolerability of SCT630 and to establish pharmacokinetic similarity of SCT630 to adalimumab.

Timeline

Start
2019-05-29
Primary completion
2019-11-04
Completion
2019-11-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Adalimumab Monoclonal antibody — Subcutaneous
Subject SCT630 Unknown — Subcutaneous

Indications

No indication recorded.